101 related articles for article (PubMed ID: 1647955)
21. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
[TBL] [Abstract][Full Text] [Related]
22. The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial.
Joss RA; Galeazzi RL; Bischoff AK; Pirovino M; Ryssel HJ; Brunner KW
Clin Pharmacol Ther; 1986 Jun; 39(6):619-24. PubMed ID: 3519041
[TBL] [Abstract][Full Text] [Related]
23. [Benefit and risk of high-dose metoclopramide in comparison to high-dose haloperidol or triflupromazine in cisplatin-induced vomiting].
Saller R; Hellenbrecht D
Klin Wochenschr; 1985 May; 63(9):428-32. PubMed ID: 4039775
[TBL] [Abstract][Full Text] [Related]
24. [A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine].
Nino S; Umehara H; Inoue I; Tamura T; Sasaki Y; Sakurai M; Shinkai T; Eguchi K; Saijo N; Suemasu K
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2881-4. PubMed ID: 3310905
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study.
Grunberg SM; Gala KV; Lampenfeld M; Jamin D; Johnson K; Cariffe P; Strych D; Krailo M
J Clin Oncol; 1984 Jul; 2(7):782-7. PubMed ID: 6539812
[TBL] [Abstract][Full Text] [Related]
26. Effective control of moderate-dose cisplatin-induced emesis by a short-course regimen including metoclopramide, chlorpromazine and hydrocortisone: results of a randomized trial with metoclopramide alone.
Pollera CF; Calabresi F
Oncology; 1989; 46(4):238-44. PubMed ID: 2740067
[TBL] [Abstract][Full Text] [Related]
27. Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin.
Warrington PS; Allan SG; Cornbleet MA; MacPherson JS; Smyth JF; Leonard RC
Br Med J (Clin Res Ed); 1986 Nov; 293(6558):1334-7. PubMed ID: 3790968
[TBL] [Abstract][Full Text] [Related]
28. Antiemetic combination for cisplatin-induced emesis. Results from a controlled study.
Martín Jiménez M; Diaz-Rubio E
Bull Cancer; 1986; 73(3):294-8. PubMed ID: 3756365
[TBL] [Abstract][Full Text] [Related]
29. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
Sledge GW; Einhorn L; Nagy C; House K
Cancer; 1992 Nov; 70(10):2524-8. PubMed ID: 1423181
[TBL] [Abstract][Full Text] [Related]
30. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
[TBL] [Abstract][Full Text] [Related]
31. High-dose versus low-dose metoclopramide in the prevention of cisplatin-induced emesis. A randomized crossover study in patients with ovarian carcinoma.
Onsrud M; Moxnes A; Sollien A; Grande T; Solesvik O
Cancer; 1988 Jun; 61(12):2429-32. PubMed ID: 3365665
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group.
Seynaeve C; Schuller J; Buser K; Porteder H; Van Belle S; Sevelda P; Christmann D; Schmidt M; Kitchener H; Paes D
Br J Cancer; 1992 Jul; 66(1):192-7. PubMed ID: 1386245
[TBL] [Abstract][Full Text] [Related]
33. Comparison of intravenous granisetron with metoclopramide in the treatment of chemotherapy-induced emesis.
Chiou TJ; Wei CH; Hsieh RK; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jul; 56(1):23-30. PubMed ID: 7553406
[TBL] [Abstract][Full Text] [Related]
34. Improved benefit/risk ratio of higher-dose metoclopramide therapy during cisplatin-induced emesis.
Saller R; Hellenbrecht D; Hellstern A; Hess H
Eur J Clin Pharmacol; 1985; 29(3):311-2. PubMed ID: 4076327
[TBL] [Abstract][Full Text] [Related]
35. Antiemetic efficacy of moderately high-dose metoclopramide in patients receiving varying doses of cisplatin. Controlled comparison with a combination of methylprednisolone and metoclopramide.
Ell C; König HJ; Brockmann P; Domschke S; Domschke W
Oncology; 1985; 42(6):354-7. PubMed ID: 4069550
[TBL] [Abstract][Full Text] [Related]
36. Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin.
Cleri LB; Kris MG; Tyson LB; Pisters KM; Clark RA; Gralla RJ
Cancer; 1995 Sep; 76(5):774-8. PubMed ID: 8625179
[TBL] [Abstract][Full Text] [Related]
37. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial.
Warr D; Wilan A; Venner P; Pater J; Kaizer L; Laberge F; Latreille J; Stewart D; O'Connell G; Osoba D
Eur J Cancer; 1992; 29A(1):33-6. PubMed ID: 1332737
[TBL] [Abstract][Full Text] [Related]
38. Comparison of two different high doses of metoclopramide in the prevention of chemotherapy-induced emesis.
van Groeningen CJ; Gall HE; Simons KA; van Loenen AC; Knobf MK; Nauta J; Vermorken JB; Pinedo HM
Neth J Med; 1989 Dec; 35(5-6):283-94. PubMed ID: 2699653
[TBL] [Abstract][Full Text] [Related]
39. Prochlorperazine and transdermal scopolamine added to a metoclopramide antiemetic regimen. A controlled comparison.
Malone JM; Christensen CW; Yashinsky D; Malviya VK; Deppe G
J Reprod Med; 1990 Oct; 35(10):932-4. PubMed ID: 2246759
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
Harman GS; Omura GA; Ryan K; Hainsworth JD; Cramer MB; Hahne WF
Cancer Chemother Pharmacol; 1996; 38(4):323-8. PubMed ID: 8674154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
